Private company
Gamida Cell Ltd.
Biological products company. Summary from the record
Last updated Oct 19, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2023
Where the money goes
Where each dollar of revenue went, fiscal 2023
- Cost of revenue2¢$1.5M
- Research and development31¢$24.3M
- Selling, general and admin57¢$44.6M
- Interest10¢$7.6M
Out of $1.8M in revenue.3 The company lost money this year.
Financial statements
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.8M3 | ||||||
| Cost of revenue | $1.5M3 | ||||||
| Research and development | $1.1M6 | $50.2M7 | $42.7M3 | $24.3M3 | |||
| Selling, general and admin | $32.3M3 | $44.6M3 | |||||
| Operating expenses | $359.0K7 | $75.0M3 | $73.4M3 | ||||
| Operating income | -$19.5M4 | -$33.6M5 | -$48.2M5 | -$60.9M6 | -$87.2M7 | -$75.0M3 | -$73.0M3 |
| Interest | $5.7M3 | $7.6M3 | |||||
| Income before tax | $89.8M6 | ||||||
| Net income | -$19.0M4 | -$52.9M5 | -$34.4M5 | -$61.6M6 | -$89.8M7 | -$79.4M3 | -$63.0M3 |
| Earnings per share | $27.564 | $10.535 | $1.175 | $1.665 | $1.243 | $0.573 | |
| Earnings per share (diluted) | $27.564 | $10.535 | $1.695 | $1.665 | $1.243 | $0.573 | |
| Shares (weighted, basic) | 59.2M shares7 | 63.8M shares3 | 110.0M shares3 | ||||
| Shares (weighted, diluted) | 59.2M shares7 | 63.8M shares3 | 110.0M shares3 |
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Cash | $21.3M5 | $40.3M5 | $41.8M6 | $127.2M6 | $55.9M7 | $64.7M3 | $46.6M3 |
| Receivables | $1.6M3 | ||||||
| Inventory | $1.9M3 | ||||||
| Current assets | $130.3M6 | $98.6M7 | $66.5M3 | $54.5M3 | |||
| Property, plant and equipment | $35.2M7 | $44.3M3 | $41.3M3 | ||||
| Total assets | $44.9M11 | $65.2M4 | $68.8M5 | $158.3M6 | $148.8M7 | $124.8M3 | $102.2M3 |
| Accounts payable | $8.3M7 | $6.4M3 | $1.9M3 | ||||
| Current liabilities | $21.5M6 | $25.4M7 | $24.9M3 | $25.2M3 | |||
| Long-term debt | $4.2M3 | $4.2M3 | |||||
| Long-term liabilities | $79.4M7 | $107.9M3 | $79.9M3 | ||||
| Total liabilities | $132.8M3 | $105.1M3 | |||||
| Retained earnings | -$416.8M3 | -$479.8M3 | |||||
| Shareholders’ equity | $23.0M5 | $24.7M5 | $53.6M6 | $128.9M7 | $43.9M3 | -$8.0M3 | -$2.9M3 |
| Shares outstanding | 24.9M shares11 | 33.7M shares4 | 59.0M shares5 | 60.0M shares7 | 74.6M shares3 | 144.4M shares3 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -$16.5M4 | -$26.4M5 | -$37.9M5 | -$50.2M6 | -$81.8M7 | -$70.4M3 | -$79.1M3 |
| Depreciation and amortization | $4317 | $4407 | |||||
| Stock-based compensation | $4.2M7 | $5.0M3 | $5.5M3 | ||||
| Capital spending | $402.0K4 | $1.6M5 | $3.1M5 | $11.8M6 | $15.1M7 | $6.4M3 | $1.1M3 |
| Free cash flow | -$17.0M | -$28.1M | -$41.0M | -$62.0M | -$96.8M | -$76.8M | -$80.2M |
| Cash from investing | -$60.9M7 | $34.0M3 | -$810.0K3 | ||||
| Cash from financing | $71.4M7 | $45.1M3 | $61.8M3 |
Leadership
Who has led Gamida Cell Ltd., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2025
- Chief executive officerJulian Adams Jan 3, 2022 to Aug 10, 202212
- Chief financial officerMary Theresa Coelho May 25, 2023 to Jun 14, 202313
- Chief financial officerShai Lankry Jan 3, 2022 to Feb 10, 202314
- Chief operating officerMichele Ilene Korfin Jan 3, 2022 to Feb 2, 202415
Board members and other officers (12)
- CMO & Chief Scientific OfficerRonit Simantov Feb 10, 2023 to Feb 2, 202416
- Board memberJeremy Blank Aug 15, 2023 to Aug 15, 202317
- Board memberJulian Adams Jan 3, 2022 to Feb 2, 202412
- Board memberKenneth I. Moch Jan 3, 2022 to Feb 2, 202418
- Board memberOfer Gonen Jan 3, 2022 to Jan 3, 202219
- Board memberRobert I. Blum Jan 3, 2022 to Feb 10, 202320
- Board memberShawn Tomasello Jan 3, 2022 to Feb 2, 202421
- Board memberStephen T. Wills Jan 3, 2022 to Feb 2, 202422
- Board memberAnat Cohen-Dayag Jan 31, 2022 to Feb 10, 202323
- Board memberNaama Halevi-Davidov Jan 31, 2022 to Feb 10, 202324
- Board memberIvan M. Borrello Jun 10, 2022 to Feb 2, 202425
- General counselJoshua F. Patterson Jan 3, 2022 to Feb 2, 202426
Timeline
- Jan 3, 2022New chief executive Julian Adams becomes CEO12
Filings
200 filings to the SEC since October 2021: 3 annual reports, 7 quarterly reports, 47 major events, 66 insider forms, 27 large holders, 50 other. The latest 20:
- May 24, 202415-12G EDGAR
- May 24, 20248-K CURRENT REPORT EDGAR
- May 23, 202410-Q QUARTERLY REPORT EDGAR
- May 16, 2024NT 10-Q NOTIFICATION OF LATE FILING EDGAR
- May 13, 2024EFFECT EDGAR
- May 13, 2024EFFECT EDGAR
- May 13, 2024EFFECT EDGAR
- May 10, 20248-K/A AMENDMENT NO. 4 TO FORM 8-K EDGAR
- May 9, 2024S-8 POS POST-EFFECTIVE AMENDMENTS TO FORM S-8 EDGAR
- May 9, 2024S-8 POS POST-EFFECTIVE AMENDMENTS TO FORM S-8 EDGAR
- May 9, 2024S-8 POS POST-EFFECTIVE AMENDMENTS TO FORM S-8 EDGAR
- May 9, 2024POS AM POST-EFFECTIVE AMENDMENTS TO FORM S-3 EDGAR
- May 9, 2024POS AM POST-EFFECTIVE AMENDMENTS TO FORM S-3 EDGAR
- May 9, 2024POS AM POST-EFFECTIVE AMENDMENTS TO FORM S-3 EDGAR
- Apr 22, 20248-K CURRENT REPORT EDGAR
- Apr 11, 20248-K/A AMENDMENT NO. 3 TO FORM 8-K EDGAR
- Apr 5, 20248-K/A AMENDMENT NO. 2 TO FORM 8-K EDGAR
- Apr 1, 2024SC 13G/A EDGAR
- Mar 29, 20248-K/A AMENDMENT NO. 1 TO FORM 8-K EDGAR
- Mar 27, 202410-K ANNUAL REPORT EDGAR
The 200 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
4 open-market trades by officers, directors and large owners since October 2021: 4 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 30, 2022 | WILLS STEPHEN TDirector | Buy | 9,677 | $1.55 | $15.0K | Form 4 |
| Sep 30, 2022 | Tomasello ShawnDirector | Buy | 9,677 | $1.55 | $15.0K | Form 4 |
| Sep 30, 2022 | Blum Robert IDirector | Buy | 50,000 | $1.55 | $77.5K | Form 4 |
| Sep 30, 2022 | Jenkins Abigail L.President and CEO | Buy | 16,129 | $1.55 | $25.0K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- LEVIN CAPITAL STRATEGIES, L.P.SC 13G/A, 2 filings Feb 8, 2024 to Apr 1, 202427
- CVI Investments, Inc.SC 13G/A, 2 filings Apr 24, 2023 to Feb 14, 202428
- Rock Springs Capital Management LPSC 13G/A, 1 filing Feb 14, 202429
- Stonepine Capital Management, LLCSC 13G/A, 3 filings May 1, 2023 to Feb 13, 202430
- FMR LLCSC 13G/A, 3 filings Feb 9, 2022 to Feb 9, 202431
- HIGHBRIDGE CAPITAL MANAGEMENT LLCSC 13G/A, 3 filings Feb 11, 2022 to Feb 2, 202432
- AI Gamida Holdings LLCSC 13D/A, 7 filings Feb 8, 2022 to Nov 20, 202333
- Community US Fund Management, Inc.SC 13D/A, 3 filings Feb 14, 2023 to Nov 8, 202334
- NovartisSC 13D/A, 2 filings Mar 3, 2023 to May 26, 202335
- Consonance Capital Management LPSC 13G/A, 1 filing Feb 14, 202236
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14SEC EDGARShai Lankry, Chief financial officer
- 15
- 16
- 17SEC EDGARJeremy Blank, Board member
- 18SEC EDGARKenneth I. Moch, Board member
- 19SEC EDGAROfer Gonen, Board member
- 20SEC EDGARRobert I. Blum, Board member
- 21SEC EDGARShawn Tomasello, Board member
- 22SEC EDGARStephen T. Wills, Board member
- 23SEC EDGARAnat Cohen-Dayag, Board member
- 24SEC EDGARNaama Halevi-Davidov, Board member
- 25SEC EDGARIvan M. Borrello, Board member
- 26SEC EDGARJoshua F. Patterson, General counsel
- 27
- 28
- 29
- 30
- 31SEC EDGARFMR LLC SC 13G/A on Gamida Cell Ltd.
- 32
- 33
- 34
- 35
- 36